International Prognostic Scoring System (IPSS)

Greenberg, P., Cox, C., LeBeau et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89, 2079-2088.
Prognostic variable 0 0.5 1 (Score value) 1.5 2
Bone marrow blasts (%) <5 5 - 10  - 11 - 20  21 - 30
Karyotype* Good Intermediate  Poor
Cytopenias 0-1 2 - 3  -


*Good: normal, -Y, del(5q), del(20q)
Poor: chromosome 7 anomalies or complex (≥3 abnormalities)
Intermediate: other abnormalities.

Cytopenias defined as haemoglobin concentration <100 g/l, neutrophils <1.8 x 109/l and platelets <100 x 109/l

IPSS Prognostic Risk Categories/Scores

Low 0
Intermediate - 1 0.5 - 1
Intermediate - 2 1.5 - 2
 High ≥2.5

Paper of the Month

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Visit our archives

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator


Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here